FDA Selects Perspective Therapeutics To Participate In The CDRP Program To Expedite Chemistry, Manufacturing, and Controls Development Readiness For VMT-α-NET in Neuroendocrine Tumors
FDA Selects Perspective Therapeutics To Participate In The CDRP Program To Expedite Chemistry, Manufacturing, and Controls Development Readiness For VMT-α-NET in Neuroendocrine Tumors
FDA選擇Persective Therapeutics參與CDRP計劃，以加快神經內分泌腫瘤中VMT-α-Net的化學、製造和控制開發準備工作
FDA Selects Perspective Therapeutics To Participate In The CDRP Program To Expedite Chemistry, Manufacturing, and Controls Development Readiness For VMT-α-NET in Neuroendocrine Tumors
FDA選擇Persective Therapeutics參與CDRP計劃，以加快神經內分泌腫瘤中VMT-α-Net的化學、製造和控制開發準備工作
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。